LILIAN BARNES: Open Payments
NPI 1104458116 · KANSAS CITY, MO. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,434 in 158 payments from 17 companies in 2025. Trend: 2023 $2,219 · 2024 $3,376 · 2025 $3,434
Food & beverage: $3,258Education: $176
| Company | Payments | Amount |
|---|---|---|
| Janssen Biotech, Inc. | 29 | $904 |
| ABBVIE INC. | 34 | $632 |
| Takeda Pharmaceuticals U.S.A., Inc. | 19 | $353 |
| Ardelyx, Inc. | 14 | $286 |
| Lilly USA, LLC | 9 | $257 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 11 | $200 |
| Madrigal Pharmaceuticals | 9 | $144 |
| Celltrion USA Inc. | 7 | $142 |
| GENZYME CORPORATION | 4 | $109 |
| Aimmune Therapeutics, Inc. | 4 | $87 |
Products named: TREMFYA, RINVOQ, ENTYVIO, IBSRELA, OMVOH, XIFAXAN, SKYRIZI, DUPIXENT.
Industry payments across MO — which companies pay providers there.
